Commentary
Video
Dr Grinshpun on Ultra-Sensitive ctDNA Detection in HR+ Early Breast Cancer
Albert Grinshpun, MD, MSc, discusses the utility of ctDNA as a predictive biomarker of endocrine therapy sensitivity in patients with HR+ breast cancer.
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center, discusses a study evaluating the potential utility of circulating tumor DNA (ctDNA) as a predictive biomarker of endocrine therapy sensitivity in patients with hormone receptor (HR)–positive early breast cancer.
Related Videos
Related Content
